Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03378128 · ClinicalTrials.gov registry record · NA

Debulking Surgery in Ovarian Cancer

A NA study, sponsored by Case Comprehensive Cancer Center.

Completed
Registry status
NA
Development phase
50
Enrollment target

NCT03378128 is a NA study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 50 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03378128, a NA study, has completed, sponsored by Case Comprehensive Cancer Center.

COMPLETED
Registry status
NA
Development phase
50 participants
Enrollment target

Study Summary

The purpose of this study is to see if patients undergoing a laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy (neoadjuvant- chemotherapy given before surgery) is feasible, safe, and provides similar outcomes as compared to undergoing a large abdominal incision. Minimally invasive, or laparoscopic, surgery is a type of surgery where only small incisions are made on the abdomen and surgical instruments are placed through these incisions to perform the surgery. This type of surgery has been shown to improve outcomes in many types of surgery, including in gynecologic cancer surgery. Specifically, researchers know that patients who have minimally invasive surgery have less pain after surgery, can go home quicker from the hospital, healing time is more rapid, and potentially this can translate into returning to chemotherapy sooner. Specifically, in ovarian, fallopian tube, and primary peritoneal cancer, minimally invasive surgery has not been used as much because these cancers can have tumors all throughout the inside of the abdomen (i.e. wide tumor burden) and located in areas that are sometimes not easily reachable with laparoscopic instruments. However, the reason patients receive neoadjuvant chemotherapy is to shrink the tumor/s to make the surgery less extensive and the recovery easier. It is unknown if minimally invasive surgery can be used in this setting and by studying this, the study team will be able to determine if patient outcomes are improved by implementing (using) this surgical technique.

Interventions

  • PROCEDURE Diagnostic laparoscopy

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2018-01-12
Est. Completion 2020-04-30
Phase NA

Sponsor

Case Comprehensive Cancer Center

407 total trials

What the Registry Record Tells You About NCT03378128

The ClinicalTrials.gov registry entry for NCT03378128 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Diagnostic laparoscopy is the first listed.

NCT03378128 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT03378128 about?

NCT03378128 is a clinical study titled "Debulking Surgery in Ovarian Cancer". The purpose of this study is to see if patients undergoing a laparoscopic surgery for removal of ovarian, fallopian tube, or primary peritoneal cancer following neoadjuvant chemotherapy (neoadjuvant- chemotherapy given before surgery) is feasible, safe, and provides similar outcomes as compared to u...

What is the current status of trial NCT03378128?

This trial is currently completed. It is a NA study. The enrollment target is 50 participants. The study started on 2018-01-12. Estimated completion is 2020-04-30.

What interventions are being tested in trial NCT03378128?

The interventions under investigation include: Diagnostic laparoscopy (PROCEDURE).

Who is sponsoring clinical trial NCT03378128?

This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.